Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?

Clinical Therapeutics

Volumn 26, Issue SUPPL. A, 2004, Pages

  Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive; Blood pressure; Hypertension; Sartan

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTACID AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; SARTAN; UNCLASSIFIED DRUG; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; BIOAVAILABILITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LIFESTYLE; METABOLISM; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 2342590055     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90142-7     Document Type: Article

References (16)

1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960-1991 [published correction appears in Hypertension. 1996;27:1192]. Hypertension. 1995;26:60-69.
2. Hense HW. Epidemiology of arterial hypertension and implications for its prevention. 10-year results of the MONICA Study Augsburg [in German]. Dtsch Med Wochenschr. 2000;125:1397-1402.
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [published correction appears in Arch Intern Med. 1998;158:573]. Arch Intern Med. 1997;157:2413-2446.
4. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Press. 1998;7:313-315.
5. Waeber B, Vetter W, Darioli R, et al. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract. 1999;53:37-38.
6. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-547.
7. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Can J Cardiol. 1997; 13:914-920.
8. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. Can Med Assoc J. 1999;160:41-46.
9. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998; 20:671-681.
10. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. Boston/Toronto/London: Little, Brown; 1993:249-281.
11. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: An important step in patient management. J Hypertens. 2003;21(Suppl 2):S37-S42.
12. Holzgreve H. Antihypertensive therapy with fixed combinations [in German]. Internist (Berl). 1996;37:852-856.
13. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-527.
14. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risks of clinically relevant drug interaction. J Hypertens. 2001;19(Suppl 1):S21-S32.
15. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview. J Hum Hypertens. 2002;16(Suppl 2):S13-S16.
16. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:3-27.